NON-COMMERCIAL SOFTWARE LICENSE

This Non-Commercial Software License is effective the day of the last signature set forth below between Cornell University (“Cornell”) as represented by its Center for Technology Licensing (“CTL”) having an office at 395 Pine Tree Road, Suite 310, Ithaca, NY 14850, and the user of the MRDetect package or any each script within it (“LICENSEE”).

This Agreement is effective on the date the MRDetect package or any script within it (the “Software”) is downloaded by LICENSEE (the “Effective Date”), and downloading the Software constitutes acceptance of these conditions.

RECITALS

The Software was authored by employees of Cornell and New York Genome Center, Inc. (“NYGC”) under the direction of Dan Landau, and is described in Cornell docket D-9097, D-9098, D-9099, and D-9100. Algorithms that the Software executes and methods to use the Software are described in Cornell docket D-7874 entitled “Ultra-sensitive Detection of Circulating Tumor DNA through Genome-wide Integration” and in Cornell docket D-8206, entitled “Systems and Methods for Detection of Residual Disease” which are owned by Cornell, NYGC, and The Broad Institute, Inc. (“Broad”) (the “Inventions”).

Cornell has been authorized by NYGC to manage the Software and copyrights therein, and Cornell has been authorized by NYGC and Broad to manage the Inventions and Patent Rights, under interinstitutional agreements. “Patent Rights” means Cornell’s rights in published PCT applications WO2019169042 and WO2019169044 covering the Inventions, and any patent applications claiming priority thereto, including divisions, continuations, or continuations in part (but only to the extent such continuations in part are supported by the written description in the parent application) thereof; any corresponding foreign applications thereof; and any U.S. or joint foreign patents issued thereon or reissues, renewals, substitutions or extensions thereof.

LICENSEE desires to use the Software to a) replicate the results published in the paper, “Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring” published in Nature Medicine (the “Paper”) pursuant to Nature’s policy on code sharing; or b) for non-commercial, academic research. (“Purpose”).

Cornell makes the Software available to the LICENSEE on the terms and conditions set forth below.

NOW, THEREFORE, in consideration of the mutual covenants and obligations hereinafter set forth, the parties hereto hereby agree as follows:

1. LICENSEE represents that he or she is either a) an employee of a nonprofit research institution or b) will use the Software and rights granted herein solely to replicate the results published in the Paper.
2. LICENSEE will use the Software only for the Purpose and in compliance with all applicable statutes and regulations, including export laws. LICENSEE will cite the Paper in any publication or presentation of results using the Software.

3. Cornell grants LICENSEE, solely for the performance of the Purpose by LICENSEE:
   a) a nonexclusive license under copyright to download, execute and display the Software, and
   b) a nonexclusive license under Patent Rights.
This grant is to LICENSEE alone and is not transferable, assignable, or sublicensable, and **does not include the right to make derivative works of Software**. Without limitation to the immediately preceding sentence, should LICENSEE make any derivative works of Software outside the rights granted herein, LICENSEE hereby assigns to Cornell all right, title and interest in and to any and all such derivative works, and LICENSEE may continue to use such derivative works solely for the Purpose; provided, that in no event shall LICENSEE authorize and permit any third party to use such derivative works. LICENSEE hereby agrees to execute any documents and do any other acts which are consistent herewith as may be reasonably required by Cornell or its assignees or licensees to further evidence or effectuate Cornell’s rights as set forth in this license agreement (including, without limitation, Paragraph 3 hereof). If and upon LICENSEE’s failure promptly to do so, after a reasonable opportunity to review same, LICENSEE hereby appoints Cornell as its attorney-in-fact solely for such purposes (it being acknowledged that such appointment is irrevocable and a power coupled with an interest) with full power of substitution and delegation.

4. Nothing in this Agreement grants LICENSEE:
   a) any rights to use Software or Patent Rights for profit-making or for commercial research by LICENSEE or any sponsor or affiliate of LICENSEE, or any other use outside the Purpose;
   b) any rights in any copyright or patent rights owned or controlled by Cornell, Broad, or NYGC other than those rights explicitly granted herein.
Nothing in this Agreement obligates Cornell, NYGC, or Broad to provide updates or bug fixes to Software, or to provide information to LICENSEE not included in Software.

5. LICENSEE understands that the Software delivered hereby is experimental in nature, and each of Cornell, NYGC, and Broad MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE SOFTWARE OR PATENT RIGHTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES.

6. In no event shall Cornell, NYGC, Broad, their affiliates, or their current and former directors, trustees, officers, employees, faculty, affiliated investigators, students, and agents and their respective successors, heirs and assigns be liable for incidental or consequential damages of any kind, including, without limitation, economic damages or injury to property and lost profits for activities which may arise from or in connection with this Agreement or with the use of the Software hereunder. LICENSEE hereby holds Cornell, NYGC, Broad, their affiliates, or their current and former directors, trustees, officers, employees, faculty, affiliated investigators, students, and agents and their respective successors, heirs and assigns harmless
from any loss, claim, damage, or liability, of whatsoever kind or nature, which may arise from
or in connection with this Agreement or with the use of the Software hereunder.

7. LICENSEE has the right to terminate this Agreement for any reason upon written notice to
Cornell. Cornell has the right to terminate this Agreement if Licensee breaches this
Agreement, which termination will be effective on the date the notice of termination is sent.
Upon termination, LICENSEE shall provide Cornell with written assurance that the original
and all copies of the Software have been destroyed, except that, upon prior written
authorization from Cornell, LICENSEE may retain a copy for archive purposes. Paragraphs
2, 4, 5, 6, 7, and 8 will survive termination.

8. Software transferred hereunder by Cornell to LICENSEE shall remain the property of NYGC
or of NYGC and Cornell.

9. Nothing in this Agreement confers any right to use in advertising, publicity, or other
promotional activities any name, trade name, trademark, or other designation of Cornell,
NYGC, or Broad. Unless required by law, the use by LICENSEE of the name, “Cornell
University” is prohibited, without the express written consent of Cornell, the name “New
York Genome Center” or any variation, adaptation, or abbreviation thereof, or of any of their
trustees, directors, officers, faculty, students, staff, employees, agents, or affiliated
investigators or any trademark owned by NYGC, is prohibited, without the express written
consent of NYGC, and the name “The Broad Institute, Inc.” or any variation, adaptation, or
abbreviation thereof, or of any of their trustees, directors, officers, faculty, students, staff,
employees, agents, or affiliated investigators or any trademark owned by Broad, is prohibited,
without the express written consent of Cornell.

10. This Agreement shall be construed, governed, interpreted and applied in accordance with the
internal laws of the state of New York, U.S.A., without regard to conflict of laws principles,
except that the scope and validity of any patent or patent application within Patent Rights are
governed by the applicable laws of the country of that patent or patent application.

11. This Agreement is the complete agreement between the parties regarding its subject matter
and supersedes any prior oral or written communications or understandings between the
parties related to its subject matter. No modification, amendment or waiver may be
accomplished to the terms of this Agreement without the written consent of both parties.